Posts Tagged: "COVID-19 Prioritized Examination Pilot Program"

USPTO Launches COVID-19 Fast-Track Appeals Pilot as Companion to Prioritized Examination Pilot

The United States Patent and Trademark Office (USPTO) announced yesterday that it will launch a COVID-19 fast-track appeals pilot program beginning today. The pilot is a companion to the COVID-19 Prioritized Examination Pilot Program launched last year. The latest pilot will allow an appellant to have certain COVID-19-related ex parte appeals before the Patent Trial and Appeal Board (PTAB) accorded fast-track status. The appeal must be related to an application that claims a product or process that is subject to an applicable Food and Drug Administration (FDA) approval for COVID–19 use. These may include, “but are not limited to, an Investigational New Drug (IND) application, an Investigational Device Exemption (IDE), a New Drug Application (NDA), a Biologics License Application (BLA), a Premarket Approval (PMA), or an Emergency Use Authorization (EUA).”